Nemonoxacin achieved a better symptomatic improvement and a prolonged interval to next exacerbation than moxifloxacin for outpatients with acute exacerbations of chronic obstructive pulmonary disease

Nemonoxacin is a novel non-fluorinated quinolone with strong antibacterial efficacy, but data of its effect on acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is rare. This study was conducted to compare the efficacy of oral nemonoxacin with moxifloxacin in AECOPD outpatients....

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Weiwei, Zeng, Huihui, Zhao, Zhiqi, Xiong, Ruoyan, Chen, Yan, Li, Zhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560244/
https://www.ncbi.nlm.nih.gov/pubmed/37805617
http://dx.doi.org/10.1038/s41598-023-44188-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560244/
https://www.ncbi.nlm.nih.gov/pubmed/37805617
http://dx.doi.org/10.1038/s41598-023-44188-2

Ejemplares similares